201 related articles for article (PubMed ID: 36302346)
1. Rituximab in Subepidermal Blistering Diseases.
Tan WH; Sim J; Sultana R; Lee HY
Dermatology; 2023; 239(1):5-11. PubMed ID: 36302346
[TBL] [Abstract][Full Text] [Related]
2. Bullous autoimmune dermatoses.
Hofmann SC; Juratli HA; Eming R
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
[TBL] [Abstract][Full Text] [Related]
3. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A
Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538
[TBL] [Abstract][Full Text] [Related]
4. Bullous Pemphigoid and Other Pemphigoid Dermatoses.
Pratasava V; Sahni VN; Suresh A; Huang S; Are A; Hsu S; Motaparthi K
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684098
[TBL] [Abstract][Full Text] [Related]
5. Nutrition and bullous diseases.
Stoj V; Lu J
Clin Dermatol; 2022; 40(2):156-165. PubMed ID: 34808244
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
7. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of autoimmune blistering diseases.
Kasperkiewicz M; Schmidt E
Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
11. Treatment of subepidermal immunobullous diseases.
Culton DA; Diaz LA
Clin Dermatol; 2012; 30(1):95-102. PubMed ID: 22137232
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
13. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
Li Y; Foshee JB; Sontheimer RD
J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
15. New and emerging therapies in the treatment of blistering diseases.
Korman NJ
Dermatol Clin; 2000 Jan; 18(1):127-37, ix-x. PubMed ID: 10626118
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B
J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
[TBL] [Abstract][Full Text] [Related]
17. [Bullous autoimmune dermatoses of the mucous membranes].
Didona D; Hinterseher J; Eming R
Dermatologie (Heidelb); 2022 Sep; 73(9):692-700. PubMed ID: 36006424
[TBL] [Abstract][Full Text] [Related]
18. New immunomodulating drugs in autoimmune blistering diseases.
Korman NJ
Dermatol Clin; 2001 Oct; 19(4):637-48, viii. PubMed ID: 11705351
[TBL] [Abstract][Full Text] [Related]
19. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
Wallet-Faber N; Franck N; Batteux F; Mateus C; Gilbert D; Carlotti A; Avril MF; Dupin N
Dermatology; 2007; 215(3):252-5. PubMed ID: 17823525
[TBL] [Abstract][Full Text] [Related]
20. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
